Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
My Lists

True North Therapeutics

951 Gateway Blvd.
So. San Francisco, CA 94080
(650) 872-4700
Website Company Summary Management Team

CEO: Nancy F. Stagliano (9/4/2013)
General Management: Adam Rosenthal (9/4/2013) ; Graham Parry (9/4/2013) ; Sandip Panicker (4/30/2015) ; James C. Gilbert (6/17/2014)
Finance: Karen C. Lam

Outside board: (May no longer be on the board) Isaac Manke (New Leaf Venture Partners Partner) Carl L. Gordon (OrbiMed Founding Partner) Rajeev Dadoo (SR One Limited Partner) Jim Scopa (MPM Capital Managing Director) Beth Seidenberg (Kleiner Perkins Partner) Peter Van Vlasselaer (Arresto Biosciences Former Founding CEO)
Former outside board: Geeta Vemuri (Baxter Ventures VP)

Business description: True North Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class product candidates for Complement-mediated diseases. The company’s lead product candidate, TNT009, is designed to selectively inhibit a target in the Classical Complement pathway. True North’s antibody drug development is focused on the treatment of certain rare diseases mediated by the Complement system in hematology, transplantation, and dermatology. True North Therapeutics is located in South San Francisco, California.

Rounds: 5
Capital raised: 142.0M
Last Round: 45.0M
Ownership: Private  
VCs include: Kleiner Perkins MPM Capital OrbiMed SR One Limited New Leaf Venture Partners Mission Bay CapitalRedmile Group ;  Cowen Private Investments ;  Baxalta Ventures;  HBM Healthcare Investments AG
Corporate investors: Biogen Idec New Ventures ;  Baxter Ventures

Last Tweets


Last Mentions

Record updated: Oct 2016
Sector: Medical
Year Founded: 2013
Headcount: 11-25 as of Oct 2016
Rounds: 5
Capital Raised: 142.0M
Last Round: 45.0M
Ownership: Private